Co-inhibition of CD73 and A2AR Adenosine Signaling Improves Anti-tumor Immune Responses

PD-1 blockade induces responses by inhibiting adaptive immune resistance

Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609

The immune contexture in human tumours: impact on clinical outcome

Fridman, W. H., Pagès, F., Sautès-Fridman, C., & Galon, J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3245 · Cited by 4,981

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma

Simpson, T. R., Li, F., Montalvo-Ortiz, W., Sepulveda, M. A., Bergerhoff, K., Arce, F., Roddie, C., Henry, J. Y., Yagita, H., Wolchok, J. D., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130579 · Cited by 1,472

Classifying Cancers Based on T-cell Infiltration and PD-L1

Teng, M. W. L., Ngiow, S. F., Ribas, A., & Smyth, M. J. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0255 · Cited by 1,411

Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage

Ohta, A., & Sitkovsky, M. (2001) · Nature · doi:10.1038/414916a · Cited by 1,334

A2A adenosine receptor protects tumors from antitumor T cells

Ohta, A., Gorelik, E., Prasad, S. J., Ronchese, F., Lukashev, D., Wong, M. K. K., Huang, X., Caldwell, S., Liu, K., Smith, P., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605251103 · Cited by 1,065

FcR γ chain deletion results in pleiotrophic effector cell defects

Takai, T., Li, M., Sylvestre, D., Clynes, R., & Ravetch, J. V. (1994) · Cell · doi:10.1016/0092-8674(94)90115-5 · Cited by 951

Combination cancer immunotherapies tailored to the tumour microenvironment

Smyth, M. J., Ngiow, S. F., Ribas, A., & Teng, M. W. L. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.209 · Cited by 944 · cited 1×

CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients

Ott, P. A., Hodi, F. S., & Robert, C. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0143 · Cited by 696

Ecto-5′-nucleotidase (CD73) regulation by hypoxia-inducible factor-1 mediates permeability changes in intestinal epithelia

Synnestvedt, K., Furuta, G. T., Comerford, K. M., Louis, N. A., Karhausen, J., Eltzschig, H. K., Hansen, K. R., Thompson, L. F., & Colgan, S. P. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15337 · Cited by 679

Ecto-5′-Nucleotidase (CD73) Regulation by Hypoxia-Inducible Factor-1 Mediates Permeability Changes in Intestinal Epithelia

Synnestvedt, K., Furuta, G. T., Comerford, K. M., Louis, N., Karhausen, J., Eltzschig, H. K., Hansen, K. R., Thompson, L. F., & Colgan, S. P. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215337 · Cited by 660

Tumor-associated neutrophils stimulate T cell responses in early-stage human lung cancer

Eruslanov, E. B., Bhojnagarwala, P. S., Quatromoni, J. G., Stephen, T. L., Ranganathan, A., Deshpande, C., Akimova, T., Vachani, A., Litzky, L., Hancock, W. W., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci77053 · Cited by 644

Immunological mechanisms of the antitumor effects of supplemental oxygenation

Hatfield, S. M., Kjaergaard, J., Lukashev, D., Schreiber, T. H., Belikoff, B., Abbott, R., Sethumadhavan, S., Philbrook, P., Ko, K., Cannici, R., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa1260 · Cited by 600

Immunotype and Immunohistologic Characteristics of Tumor-Infiltrating Immune Cells Are Associated with Clinical Outcome in Metastatic Melanoma

Erdag, G., Schaefer, J. T., Smolkin, M. E., Deacon, D. H., Shea, S. M., Dengel, L. T., Patterson, J. W., & Slingluff, C. L. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3218 · Cited by 590

Anti-TIM3 Antibody Promotes T Cell IFN-γ–Mediated Antitumor Immunity and Suppresses Established Tumors

Ngiow, S. F., von Scheidt, B., Akiba, H., Yagita, H., Teng, M. W. L., & Smyth, M. J. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0096 · Cited by 574

Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis

Stagg, J., Divisekera, U., McLaughlin, N., Sharkey, J., Pommey, S., Denoyer, D., Dwyer, K. M., & Smyth, M. J. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0908801107 · Cited by 572

A2AAdenosine Receptor Deficiency Attenuates Brain Injury Induced by Transient Focal Ischemia in Mice

Chen, J.-F., Huang, Z., Ma, J., Zhu, J., Moratalla, R., Standaert, D., Moskowitz, M. A., Fink, J. S., & Schwarzschild, M. A. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-21-09192.1999 · Cited by 557

Crucial Role for Ecto-5′-Nucleotidase (CD73) in Vascular Leakage during Hypoxia

Thompson, L. F., Eltzschig, H. K., Ibla, J. C., Van De Wiele, C. J., Resta, R., Morote-Garcia, J. C., & Colgan, S. P. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20040915 · Cited by 543

CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer

Loi, S., Pommey, S., Haibe-Kains, B., Beavis, P. A., Darcy, P. K., Smyth, M. J., & Stagg, J. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1222251110 · Cited by 492

Targeting CD73 Enhances the Antitumor Activity of Anti-PD-1 and Anti-CTLA-4 mAbs

Allard, B., Pommey, S., Smyth, M. J., & Stagg, J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0545 · Cited by 458

Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies

Bulliard, Y., Jolicoeur, R., Windman, M., Rue, S. M., Ettenberg, S., Knee, D. A., Wilson, N. S., Dranoff, G., & Brogdon, J. L. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130573 · Cited by 446

Impaired IgG-Dependent Anaphylaxis and Arthus Reaction in FcγRIII (CD16) Deficient Mice

Hazenbos, W. L. W., Gessner, J. E., Hofhuis, F. M. A., Kuipers, H., Meyer, D., Heijnen, I. A. F. M., Schmidt, R. E., Sandor, M., Capel, P. J. A., Daëron, M., et al. (1996) · Immunity · doi:10.1016/s1074-7613(00)80494-x · Cited by 443

Dual targeting strategies with bispecific antibodies

Kontermann, R. (2012) · mAbs · doi:10.4161/mabs.4.2.19000 · Cited by 435

Localization and Density of Immune Cells in the Invasive Margin of Human Colorectal Cancer Liver Metastases Are Prognostic for Response to Chemotherapy

Halama, N., Michel, S., Kloor, M., Zoernig, I., Benner, A., Spille, A., Pommerencke, T., von Knebel, D. M., Folprecht, G., Luber, B., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0268 · Cited by 420

FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis

Dahan, R., Sega, E., Engelhardt, J., Selby, M., Korman, A. J., & Ravetch, J. V. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.08.004 · Cited by 409

CD73-Deficient Mice Have Increased Antitumor Immunity and Are Resistant to Experimental Metastasis

Stagg, J., Divisekera, U., Duret, H., Sparwasser, T., Teng, M. W. L., Darcy, P. K., & Smyth, M. J. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4246 · Cited by 401

Blockade of A 2A receptors potently suppresses the metastasis of CD73 + tumors

Beavis, P. A., Divisekera, U., Paget, C., Chow, M. T., John, L. B., Devaud, C., Dwyer, K., Stagg, J., Smyth, M. J., & Darcy, P. K. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1308209110 · Cited by 345

Type I IFN Contributes to NK Cell Homeostasis, Activation, and Antitumor Function

Swann, J. B., Hayakawa, Y., Zerafa, N., Sheehan, K. C. F., Scott, B., Schreiber, R. D., Hertzog, P., & Smyth, M. J. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.12.7540 · Cited by 339

Adenosine Receptor 2A Blockade Increases the Efficacy of Anti–PD-1 through Enhanced Antitumor T-cell Responses

Beavis, P. A., Milenkovski, N., Henderson, M. A., John, L. B., Allard, B., Loi, S., Kershaw, M. H., Stagg, J., & Darcy, P. K. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0211 · Cited by 334

Transforming Growth Factor β1 Induces Hypoxia-inducible Factor-1 Stabilization through Selective Inhibition of PHD2 Expression

McMahon, S., Charbonneau, M., Grandmont, S., Richard, D. E., & Dubois, C. M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m604507200 · Cited by 330

Targeting Cancer-Derived Adenosine:New Therapeutic Approaches

Young, A., Mittal, D., Stagg, J., & Smyth, M. J. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0341 · Cited by 310

Myeloid Expression of Adenosine A2A Receptor Suppresses T and NK Cell Responses in the Solid Tumor Microenvironment

Cekic, C., Day, Y.-J., Sag, D., & Linden, J. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3583 · Cited by 304

OX40 engagement depletes intratumoral Tregs via activating FcγRs, leading to antitumor efficacy

Bulliard, Y., Jolicoeur, R., Zhang, J., Dranoff, G., Wilson, N. S., & Brogdon, J. L. (2014) · Immunology & Cell Biology · doi:10.1038/icb.2014.26 · Cited by 284

Radiotherapy Increases the Permissiveness of Established Mammary Tumors to Rejection by Immunomodulatory Antibodies

Verbrugge, I., Hagekyriakou, J., Sharp, L. L., Galli, M., West, A., McLaughlin, N. M., Duret, H., Yagita, H., Johnstone, R. W., Smyth, M. J., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0210 · Cited by 275

CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice

Wang, L., Fan, J., Thompson, L. F., Zhang, Y., Shin, T., Curiel, T. J., & Zhang, B. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45559 · Cited by 262

Adenosinergic Regulation of the Expansion and Immunosuppressive Activity of CD11b+Gr1+ Cells

Ryzhov, S., Novitskiy, S. V., Goldstein, A. E., Biktasova, A., Blackburn, M. R., Biaggioni, I., Dikov, M. M., & Feoktistov, I. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1101225 · Cited by 261

CD73 Is Associated with Poor Prognosis in High-Grade Serous Ovarian Cancer

Turcotte, M., Spring, K., Pommey, S., Chouinard, G., Cousineau, I., George, J., Chen, G. M., Gendoo, D. M. A., Haibe-Kains, B., Karn, T., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3569 · Cited by 257

Antimetastatic Effects of Blocking PD-1 and the Adenosine A2A Receptor

Mittal, D., Young, A., Stannard, K., Yong, M., Teng, M. W. L., Allard, B., Stagg, J., & Smyth, M. J. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0957 · Cited by 245

A Threshold Level of Intratumor CD8+ T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1

Ngiow, S. F., Young, A., Jacquelot, N., Yamazaki, T., Enot, D., Zitvogel, L., & Smyth, M. J. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-1082 · Cited by 237

Systemic oxygenation weakens the hypoxia and hypoxia inducible factor 1α-dependent and extracellular adenosine-mediated tumor protection

Hatfield, S. M., Kjaergaard, J., Lukashev, D., Belikoff, B., Schreiber, T. H., Sethumadhavan, S., Abbott, R., Philbrook, P., Thayer, M., Shujia, D., et al. (2014) · Journal of Molecular Medicine · doi:10.1007/s00109-014-1189-3 · Cited by 211

CD73-Deficient Mice Are Resistant to Carcinogenesis

Stagg, J., Beavis, P. A., Divisekera, U., Liu, M. C. P., Möller, A., Darcy, P. K., & Smyth, M. J. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0420 · Cited by 211

CD73 Expression Is an Independent Prognostic Factor in Prostate Cancer

Leclerc, B. G., Charlebois, R., Chouinard, G., Allard, B., Pommey, S., Saad, F., & Stagg, J. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1181 · Cited by 200

FcγRIV deletion reveals its central role for IgG2a and IgG2b activity in vivo

Nimmerjahn, F., Lux, A., Albert, H., Woigk, M., Lehmann, C., Dudziak, D., Smith, P., & Ravetch, J. V. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1014515107 · Cited by 200

Structural characterization of a human Fc fragment engineered for lack of effector functions

Oganesyan, V., Gao, C., Shirinian, L., Wu, H., & Dall'Acqua, W. F. (2008) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444908007877 · Cited by 197

High expression of CD73 as a poor prognostic biomarker in human colorectal cancer

Wu, X., He, X., Chen, Y., Yuan, R., Zeng, Y., Lian, L., Zou, Y., Lan, N., Wu, X., & Lan, P. (2012) · Journal of Surgical Oncology · doi:10.1002/jso.23056 · Cited by 178

Adenosine A2A Receptors Intrinsically Regulate CD8+ T Cells in the Tumor Microenvironment

Cekic, C., & Linden, J. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3581 · Cited by 174

Anti‐CD73 therapy impairs tumor angiogenesis

Allard, B., Turcotte, M., Spring, K., Pommey, S., Royal, I., & Stagg, J. (2014) · International Journal of Cancer · doi:10.1002/ijc.28456 · Cited by 171

FcγRIV is a mouse IgE receptor that resembles macrophage FcεRI in humans and promotes IgE-induced lung inflammation

Mancardi, D. A., Iannascoli, B., Hoos, S., England, P., Daëron, M., & Bruhns, P. (2008) · Journal of Clinical Investigation · doi:10.1172/jci36452 · Cited by 154

Adenosine limits the therapeutic effectiveness of anti-CTLA4 mAb in a mouse melanoma model.

Iannone, R., Miele, L., Maiolino, P., Pinto, A., & Morello, S. (2014) · Europe PMC (PubMed Central) · Cited by 129

Role of TGF-β Signaling in Generation of CD39+CD73+ Myeloid Cells in Tumors

Ryzhov, S. V., Pickup, M. W., Chytil, A., Gorska, A. E., Zhang, Q., Owens, P., Feoktistov, I., Moses, H. L., & Novitskiy, S. V. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1400578 · Cited by 126

Natural killer cells are essential for the ability of BRAF inhibitors to control BRAFV600E-mutant metastatic melanoma

Ferrari de Andrade, L., Ngiow, S. F., Stannard, K., Rusakiewicz, S., Kalimutho, M., Khanna, K. K., Tey, S.-K., Takeda, K., Zitvogel, L., Martinet, L., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1339 · Cited by 105

NK cells require IL-28R for optimal in vivo activity

Souza-Fonseca-Guimarães, F., Young, A., Mittal, D., Martinet, L., Bruedigam, C., Takeda, K., Andoniou, C. E., Degli‐Esposti, M. A., Hill, G. R., & Smyth, M. J. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1424241112 · Cited by 101

Loss of CD73-mediated actin polymerization promotes endometrial tumor progression

Bowser, J. L., Blackburn, M. R., Shipley, G. L., Molina, J. G., Dunner, K., & Broaddus, R. R. (2015) · Journal of Clinical Investigation · doi:10.1172/jci79380 · Cited by 97

Different role of CD73 in leukocyte trafficking via blood and lymph vessels

Ålgars, A., Karikoski, M., Yegutkin, G. G., Stoitzner, P., Niemelä, J., Salmi, M., & Jalkanen, S. (2011) · Blood · doi:10.1182/blood-2010-11-321646 · Cited by 68

Non-invasive quantification of brain tumor-induced astrogliosis

Lee, J., Borboa, A. K., Baird, A., & Eliceiri, B. P. (2011) · BMC Neuroscience · doi:10.1186/1471-2202-12-9 · Cited by 50

Caffeine promotes anti-tumor immune response during tumor initiation: Involvement of the adenosine A2A receptor

Eini, H., Frishman, V., Yulzari, R., Kachko, L., Lewis, E. C., Chaimovitz, C., & Douvdevani, A. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.08.092 · Cited by 47

FcγRIII and FcγRIV Are Indispensable for Acute Glomerular Inflammation Induced by Switch Variant Monoclonal Antibodies

Giorgini, A., Brown, H. J., Lock, H. R., Nimmerjahn, F., Ravetch, J. V., Verbeek, J. S., Sacks, S. H., & Robson, M. G. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.12.8745 · Cited by 43

Cancer immunoediting and resistance to T cell-based immunotherapy

O’Donnell, J. S., Teng, M. W. L., & Smyth, M. J. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0142-8 · Cited by 1,759

The ectonucleotidases CD 39 and CD 73: Novel checkpoint inhibitor targets

Allard, B., Longhi, M. S., Robson, S. C., & Stagg, J. (2017) · Immunological Reviews · doi:10.1111/imr.12528 · Cited by 927

Pharmacology of Adenosine Receptors: The State of the Art

Borea, P. A., Gessi, S., Merighi, S., Vincenzi, F., & Varani, K. (2018) · Physiological Reviews · doi:10.1152/physrev.00049.2017 · Cited by 783

Natural killer cells in antitumour adoptive cell immunotherapy

Laskowski, T. J., Biederstädt, A., & Rezvani, K. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00491-0 · Cited by 773

Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer

Derosa, L., Routy, B., Thomas, A. M., Iebba, V., Zalcman, G., Friard, S., Mazieres, J., Audigier-Valette, C., Moro-Sibilot, D., Goldwasser, F., et al. (2022) · Nature Medicine · doi:10.1038/s41591-021-01655-5 · Cited by 685